From: Pretreatment HIV drug resistance in adults initiating antiretroviral therapy in China, 2017
 | Number | Number of PDR | Prevalence (%) | Prevalence (%) | ||
---|---|---|---|---|---|---|
NNRTIs | NRTIs | PIs | ||||
Total | 1711 | 117 | 6.8 | 4.6(79/1711) | 2.2Â (38/1711) | 0.6Â (10/1711) |
High prevalence regions | 1102 | 90 | 8.2 | 5.5(61/1102) | 2.8Â (31/1102) | 0.6Â (7//1102) |
Dehong, Yunnan | 150 | 14 | 9.3 | 8.7(13/150) | 0.7Â (1/150) | 0 |
Lincang, Yunnan | 158 | 14 | 8.9 | 5.7(9/158) | 3.8Â (6/158) | 1.3Â (2/158) |
Liuzhou, Guangxi | 207 | 11 | 5.3 | 2.9(6/207) | 1.9Â (4/207) | 0.5Â (1/207) |
Nanning, Guangxi | 104 | 7 | 6.7 | 3.9(4/104) | 3.8Â (4/104) | 0 |
Liangshan, Sichuan | 279 | 34 | 12.2 | 9.0(25/279) | 3.9Â (11/279) | 1.1Â (3/279) |
Neijiang, Sichuan | 105 | 5 | 4.8 | 1.0(1/105) | 2.9Â (3/105) | 1.0Â (1/105) |
Shenzhen, Guangdong | 99 | 5 | 5.1 | 3.0(3/99) | 2.0Â (2/99) | 0 |
Moderate prevalence regions | 609 | 27 | 4.4 | 3.0(18/609) | 1.1Â (7/609) | 0.5Â (3/609) |
Chongqing | 85 | 5 | 5.9 | 2.4(2/85) | 1.2Â (1/85) | 2.4Â (2/85) |
Guizhou | 112 | 5 | 4.5 | 1.8(2/112) | 1.8Â (2/112) | 0.9Â (1/112) |
Hunan | 97 | 2 | 2.1 | 2.1(2/97) | 1.0Â (1/97) | 0 |
Beijing | 111 | 4 | 3.6 | 2.7(3/111) | 0.9Â (1/111) | 0 |
Jiangsu | 105 | 5 | 4.8 | 4.8(5/105) | 0 | 0 |
Shandong | 99 | 6 | 6.1 | 4.0(4/99) | 2.0Â (2/99) | 0 |